BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» Ofirmev sets brisk tempo for $1.3B Cadence Pharmaceuticals acquisition
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Ofirmev sets brisk tempo for $1.3B Cadence Pharmaceuticals acquisition
Feb. 12, 2014
By
Marie Powers
No Comments
The acquisition of Cadence Pharmaceuticals Inc. by Mallinckrodt plc for $14 per share in cash, or approximately $1.3 billion on a fully diluted basis, demonstrated that a single asset can still beat the drums when it comes to deal terms.
BioWorld